INO-4800

DRUG4 trials

Sponsors

Inovio Pharmaceuticals, International Vaccine Institute

Conditions

COVID-19 DiseaseCoronavirus InfectionSARS-CoV 2Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Phase 1

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

CompletedNCT04336410

Inovio PharmaceuticalsCoronavirus Infection

Start: 2020-04-03End: 2022-02-10Updated: 2022-04-15

Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19

CompletedNCT04447781

International Vaccine InstituteCoronavirus Infection, SARS-CoV 2

Start: 2020-07-15End: 2022-05-25Updated: 2022-07-18

Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

WithdrawnNCT05430958

Inovio PharmaceuticalsCoronavirus Infection

Start: 2022-10-31End: 2024-03-31Updated: 2022-11-17

Phase 2

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

TerminatedNCT04642638

Inovio PharmaceuticalsCoronavirus Infection, COVID-19 Disease, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Start: 2020-11-30End: 2022-09-13Updated: 2023-12-20

Related Papers

Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial

BMC Infectious Diseases2025-05-25

Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial

Human Vaccines & Immunotherapeutics2025-01-266 citations

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

The Journal of Infectious Diseases2022-01-2459 citations

571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster

Open Forum Infectious Diseases2021-11-012 citations

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.

2020-12-24202 citations

Understanding COVID-19 Vaccines and Their Development

Journal of Bone and Joint Surgery2020-07-316 citations

Are Genetic Vaccines the Right Weapon against COVID-19?

Molecular Therapy2020-06-0921 citations

Progress and Concept for COVID‐19 Vaccine Development

Biotechnology Journal2020-04-18115 citations